PCRX Pacira BioSciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PCRX

Price (delayed)

$26.595

Market cap

$1.06B

P/E Ratio

75.99

Dividend/share

N/A

EPS

$0.35

Enterprise value

$1.27B

?
Relative Growth: Rel. Growth: 71
Relative Strength: Rel. Strength: 64
Relative Valuation: Rel. Valuation: 63
Relative Profitability: Rel. Profitability: 62

Pacira Pharmaceuticals, Inc. is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control. Its products include EXPAREL (bupivacaine liposome injectable suspension) is a liposome injection ...

Highlights
Pacira BioSciences's EPS has surged by 192% QoQ and by 113% YoY
The company's net income has surged by 185% QoQ and by 111% YoY
The equity has declined by 11% year-on-year but it has increased by 2.8% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.pacira.com
Peers: HRTX CPIX TVRD OMER

Key stats

What are the main financial stats of PCRX

PCRX stock price

How has the Pacira BioSciences stock price performed over time
Intraday
0.06%
1 week
2.96%
1 month
-1.21%
1 year
-2.15%
YTD
2.76%
QTD
4.83%

Financial performance

How have Pacira BioSciences's revenue and profit performed over time
Revenue
$746.16M
Gross profit
$591.01M
Operating income
$19.87M
Net income
$14.64M
Gross margin
79.2%
Net margin
2%
Pacira BioSciences's net margin has soared by 186% from the previous quarter and by 111% YoY
The company's net income has surged by 185% QoQ and by 111% YoY
The company's operating income has surged by 119% YoY but it fell by 18% QoQ
PCRX's operating margin has soared by 118% YoY but it is down by 18% QoQ

Price vs fundamentals

How does PCRX's price correlate with its fundamentals

Growth

What is Pacira BioSciences's growth rate over time

Valuation

What is Pacira BioSciences stock price valuation
PCRX P/E details
P/E
75.99
P/B
1.56
P/S
1.41
EV/EBIT
38.21
EV/EBITDA
10.65
EV/Sales
1.7
Pacira BioSciences's EPS has surged by 192% QoQ and by 113% YoY
PCRX's P/E is 37% below its last 4 quarters average of 119.6
PCRX's P/B is 29% below its 5-year quarterly average of 2.2 but 4% above its last 4 quarters average of 1.5
The equity has declined by 11% year-on-year but it has increased by 2.8% since the previous quarter
The price to sales (P/S) is 46% lower than the 5-year quarterly average of 2.6
The revenue has grown by 6% YoY

Efficiency

How efficient is Pacira BioSciences business performance
PCRX's ROE has soared by 200% since the previous quarter and by 113% year-on-year
Pacira BioSciences's ROA has soared by 200% from the previous quarter and by 115% YoY
Pacira BioSciences's ROIC has soared by 142% YoY and by 14% from the previous quarter
Pacira BioSciences's return on sales has surged by 135% YoY and by 10% QoQ

Dividends

What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCRX.

Financial health

How did Pacira BioSciences financials performed over time
The total assets is 117% greater than the total liabilities
The current ratio has soared by 112% YoY and by 7% from the previous quarter
The company's quick ratio has surged by 75% YoY and by 4.3% QoQ
Pacira BioSciences's debt is 39% less than its equity
Pacira BioSciences's debt has decreased by 35% YoY
Pacira BioSciences's debt to equity has decreased by 27% YoY and by 3.2% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.